Basic science sits at the center of this dementia and brain health question.

Basic science discoveries about how Alzheimer’s disease develops in the brain have directly led to FDA-approved medications that can slow cognitive decline—a transformation that took decades but is now delivering real clinical benefit to patients. In 2023, lecanemab became the first fully FDA-approved disease-modifying therapy in over 20 years, clearing the majority of beta-amyloid plaques and slowing cognitive decline by approximately 30% in people with mild cognitive impairment or mild dementia.

This breakthrough followed from laboratory research in the 1990s and 2000s that identified amyloid-beta and tau proteins as key drivers of neurodegeneration, and subsequent decades of clinical testing to prove these insights could translate into effective treatments. Today, the translation from basic science to patient treatment is accelerating—the pipeline includes not just lecanemab and donanemab (another anti-amyloid therapy approved in 2024), but emerging approaches targeting tau, combination therapies, brain stimulation, and novel delivery methods like nasal sprays. This article explores how fundamental research discoveries move into clinical practice, what new treatments are coming, and what these advances mean for people facing cognitive decline.

How Basic Science Findings Become Approved Alzheimer’s Medications
The Current Pipeline of Basic Research Translated Into Clinical Trials
Tau-Targeting Therapies and the Shift Beyond Amyloid
Emerging Non-Antibody Approaches: From Brain Stimulation to Nasal Sprays
Protein Displacement Technology and Emerging Molecular Strategies
Biomarker Advances Enabling Precise Patient Selection
The Road Ahead—From Laboratory Discovery to Personalized Treatment
Conclusion

How Basic Science Findings Become Approved Alzheimer’s Medications

The journey from laboratory discovery to FDA-approved treatment in Alzheimer’s represents one of modern medicine’s most complex translation pathways. Starting in the 1990s, researchers discovered that amyloid-beta and tau proteins accumulate abnormally in Alzheimer’s brains, leading to neuroinflammation and neuronal death. These discoveries came from postmortem brain studies, animal models, and later from cerebrospinal fluid and PET imaging studies in living patients. Once a target was identified—such as clearing amyloid-beta—scientists designed antibodies and other molecules to attack that target, tested them in cell cultures and animal models, and then moved to human trials. Lecanemab is the success story: decades of basic research on amyloid-targeting proteins, combined with years of Phase 1, 2, and 3 clinical trials, finally resulted in an FDA approval showing that removing amyloid plaques does slow cognitive decline.

Similarly, donanemab, another anti-amyloid antibody, followed a parallel path and received FDA approval in 2024 with comparable cognitive benefits. However, a critical limitation exists: while removing amyloid helps, it doesn’t stop Alzheimer’s entirely. Lecanemab slows decline by 30%, meaning 70% of cognitive decline still occurs during the treatment period, and stopping the medication appears to allow decline to resume. This explains why researchers are now investigating combination approaches—if amyloid alone isn’t enough, perhaps targeting both amyloid and tau simultaneously will produce better outcomes. The first amyloid plus tau combination trial is now underway with 900 participants, testing whether drugs acting on both pathways arrest disease progression more effectively than single-target therapies.

How Basic Science Findings Become Approved Alzheimer's Medications

The Current Pipeline of Basic Research Translated Into Clinical Trials

As of the end of fiscal year 2024, the national Institutes of Health is funding 495 clinical trials for Alzheimer’s disease and related dementias, representing an unprecedented commitment to translating basic science into treatments. Within this portfolio, 225 or more trials are testing pharmacological and non-pharmacological interventions, while 164 trials are assessing 127 drugs currently in development: 48 of these drugs are in Phase 3 (late-stage) testing, 90 are in Phase 2 (mid-stage), and 26 are in Phase 1 (early-stage). This pipeline includes at least 25 new drug candidates with NIH funding that have advanced to human trials, with 18 in Phase 1 and 7 in Phase 2 or 3. These numbers reflect a fundamental shift in the field—basic science discoveries about how Alzheimer’s develops have created a roadmap for multiple intervention targets, and the clinical trial infrastructure now exists to test many candidates simultaneously.

A crucial distinction separates pharmacological from non-pharmacological approaches. Most attention focuses on new drugs targeting amyloid or tau, but basic research has also revealed that lifestyle factors—cognitive engagement, physical activity, cardiovascular health, sleep, social connection, and hearing correction—can influence dementia risk. In 2024, the Lancet Standing Commission identified 14 modifiable risk factors that could reduce dementia cases by 45% if addressed at a population level. This means basic science discoveries are not just producing pills; they’re generating evidence for multi-component prevention strategies. However, a limitation of the current trial landscape is that combining these non-drug interventions with new medications in formal trials remains limited, so evidence for true synergistic benefit is still emerging.

Tau-Targeting Therapies and the Shift Beyond Amyloid

While lecanemab and donanemab target amyloid-beta, basic science has equally emphasized tau proteins as a driver of neuronal destruction, and a new class of therapies is advancing to address this target. Tau proteins normally stabilize microtubules inside neurons, but in Alzheimer’s disease they become hyperphosphorylated and misfold, accumulating into tangles that disrupt cellular function and trigger neuroinflammation. Laboratory research showed that removing tau or blocking its toxic forms could preserve neuronal survival, leading to antibody-based therapies designed to clear or neutralize harmful tau. Several of these are now in clinical trials: E2814 (etalanetug) is in Phase 2 testing in mild cognitive impairment and mild Alzheimer’s patients with a study completion date set for December 2026; BIIB080 from Biogen had its Phase 2 CELIA trial fully enrolled in April 2025 with readouts expected in 2026; and BMS-986446 from Bristol Myers Squibb, an anti-MTBR-tau antibody, received FDA Fast Track Designation in 2025 for early Alzheimer’s treatment.

Second-generation tau antibodies are also advancing, with Phase 2 data expected by the end of 2025 for additional candidates including posdinemab and MK-2214. A practical limitation of tau-targeting therapies is that while basic research shows tau tangles contribute to neuronal death, tau accumulates more slowly than amyloid and appears in later stages of disease. This means tau-targeting drugs may be most effective in moderate or mild cognitive impairment stages rather than very early disease, though trials are still defining the optimal patient population and treatment window. Additionally, tau is present in other neurodegenerative diseases beyond Alzheimer’s—Parkinson’s disease, frontotemporal dementia, and chronic traumatic encephalopathy all involve tau pathology—so basic research on tau mechanisms may eventually benefit patients with these conditions too.

Tau-Targeting Therapies and the Shift Beyond Amyloid

Emerging Non-Antibody Approaches: From Brain Stimulation to Nasal Sprays

Beyond antibody-based therapies, basic science research has uncovered novel intervention strategies being translated into clinical trials through alternative mechanisms. Personalized brain stimulation represents one intriguing approach: a Phase 2 trial from Sinaptica Therapeutics conducted in late 2024 found that non-invasive brain stimulation slowed cognitive decline by 44% in people with mild-to-moderate Alzheimer’s disease. This discovery builds on decades of basic neuroscience showing that electrical or magnetic stimulation can enhance synaptic plasticity and neuronal repair. Another novel approach involves nasal spray delivery: researchers at the University of Texas Medical Branch developed a nasal spray treatment that clears harmful tau protein buildup and improves cognitive function in aged mouse models, offering a potential alternative to intravenous antibody infusions that currently require clinical visits every few weeks.

A comparison between these approaches reveals important tradeoffs. Antibody therapies like lecanemab require intravenous infusion every 4 weeks and carry a small risk of amyloid-related imaging abnormalities (ARIA)—brain microhemorrhages or microinfarcts that usually don’t cause symptoms but require MRI monitoring. Conversely, nasal spray treatments, if proven effective in human trials, could offer easier home administration, though they’re still experimental and haven’t yet completed clinical efficacy trials. Brain stimulation approaches avoid medication altogether, which appeals to patients concerned about side effects, but require specialized equipment and regular sessions, making them less practical for rural or underserved populations. The reality is that no single approach will work for all patients—the pipeline offers multiple options because basic science shows multiple pathways contribute to Alzheimer’s pathology.

Protein Displacement Technology and Emerging Molecular Strategies

Basic research into the physical structure of toxic protein aggregates has led to an entirely different therapeutic category called protein displacement technology. CT1812, developed with NIH funding, is designed to prevent neurotoxicity by displacing toxic protein aggregates at synapses rather than clearing them from the brain entirely. The idea emerged from laboratory studies showing that amyloid-beta and tau oligomers—small clusters of misfolded proteins—cause the most neuronal damage, whereas larger plaques may be inert. CT1812 completed Phase 2A trials, and Phase 2B is currently recruiting participants, testing whether displacing these toxic oligomers while leaving larger aggregates intact preserves cognitive function.

This represents a fundamentally different approach from antibody therapies that attempt to remove all amyloid, and basic research is still determining whether this selective targeting produces superior outcomes. A critical limitation of many emerging therapies is that they target one aspect of Alzheimer’s pathology—amyloid, tau, inflammation, or synaptic dysfunction—when in reality the disease involves multiple simultaneous processes. This is why combination therapy is receiving intense research focus. The first amyloid plus tau combination trial, now enrolling 900 participants across multiple sites, represents a shift in thinking driven by basic science: that targeting only one protein may be insufficient because both amyloid and tau contribute to neurodegeneration independently and through cascade effects. However, combining therapies also increases complexity, potential side effects, and cost, so identifying which patients benefit most from combination treatment—through biomarker testing—will be essential.

Protein Displacement Technology and Emerging Molecular Strategies

Biomarker Advances Enabling Precise Patient Selection

One of the most important basic science advances is the identification and validation of Alzheimer’s biomarkers—measurable indicators of disease pathology in the brain that can be detected through blood tests, cerebrospinal fluid analysis, or PET imaging. These biomarkers have transformed clinical trial design: 50 recent trials now use biomarkers as their primary outcome measure, and 47 clinical trials use amyloid PET imaging for patient eligibility screening, allowing researchers to select patients with actual brain pathology rather than relying solely on cognitive test scores. This precision is critical because cognitive decline has multiple causes, and enrolling patients with confirmed amyloid or tau pathology maximizes the chance of detecting a treatment effect.

Blood biomarkers—measured from a simple blood draw—have become particularly powerful tools derived from basic research on how pathological proteins leak into the bloodstream. Phosphorylated tau (p-tau181 and p-tau217) and plasma phosphorylated tau are increasingly used to identify people at risk for cognitive decline or with early disease, enabling earlier treatment initiation before extensive neurodegeneration occurs. This shift from clinical symptoms to biomarker-driven diagnosis reflects a sea change in Alzheimer’s medicine: early detection based on molecular evidence of pathology, combined with disease-modifying therapy, aims to prevent or delay symptom onset rather than treating symptoms after significant neuronal loss has already occurred.

The Road Ahead—From Laboratory Discovery to Personalized Treatment

The translation from basic science to approved treatment has historically taken 15 to 20 years or longer, making the acceleration of recent approvals remarkable. Lecanemab moved from Phase 3 trial initiation to FDA approval in roughly a decade, and donanemab followed within a year. This acceleration reflects not just scientific progress but also regulatory pathways that recognize the public health urgency of Alzheimer’s disease and clinical trial designs that use biomarkers and endpoint measures refined through basic research.

Looking forward to 2026 and beyond, expect readouts from Phase 2 and 3 trials for multiple tau-targeting antibodies, data from the first combination amyloid-plus-tau trials, completion of trials for personalized brain stimulation, and potentially the first human efficacy data for nasal spray and protein displacement approaches. The field’s trajectory suggests that within the next five years, multiple FDA-approved options will likely exist for slowing or delaying cognitive decline, selected based on individual biomarker profiles and disease stage. This represents the fulfillment of basic science’s promise: that understanding how a disease develops at the molecular level enables rational design of interventions that address root causes rather than just symptoms. For patients and families, this means the landscape of Alzheimer’s care will shift from a disease with few effective options to one where early detection combined with targeted treatments offers genuine hope for preserving cognitive function.

Conclusion

Basic science discoveries about amyloid, tau, and neuroinflammation in Alzheimer’s disease have translated into FDA-approved treatments and a robust pipeline of emerging therapies that show real promise in slowing cognitive decline. Lecanemab and donanemab, approved in 2023 and 2024 respectively, demonstrate that targeting disease pathology can extend cognitive function, while tau-targeting antibodies, combination therapies, brain stimulation, and novel delivery methods represent the next wave of translation from laboratory to clinic. This acceleration is underpinned by 495 NIH-funded clinical trials, biomarker advances enabling precise patient selection, and 25 or more new drug candidates in human testing.

For individuals facing cognitive decline, family members, and care partners, these advances underscore the importance of early evaluation and biomarker testing to understand individual disease pathology and access emerging treatments. The field is transitioning from a one-size-fits-all approach to precision medicine guided by decades of basic research—and for the first time, that research is delivering interventions that genuinely alter the course of disease. While current treatments slow rather than stop cognitive decline, the pace of discovery suggests that more effective approaches will emerge as basic research continues to reveal how Alzheimer’s develops and how that knowledge can be harnessed to help patients.